Dopamine and Huntington’s disease

Huntington’s disease (HD) is an incurable, inherited, progressive neurodegenerative disorder that is defined by a combination of motor, cognitive and psychiatric features. Pre-clinical and clinical studies have demonstrated an important role for the dopamine (DA) system in HD with dopaminergic dysfunction at the level of both DA release and DA receptors. It is, therefore, not surprising that the drug treatments most commonly used in HD are anti-dopaminergic agents. Their use is based primarily on the belief that the characteristic motor impairments are a result of overactivation of the central dopaminergic pathways. While this is a useful starting place, it is clear that the behavior of the central dopaminergic pathways is not fully understood in this condition and may change as a function of disease stage. In addition, how abnormalities in dopaminergic systems may underlie some of the non-motor features of HD has also been poorly investigated and this is especially important given the greater burden these place on the patients’ and families’ quality of life. In this review, we discuss what is known about central dopaminergic pathways in HD and how this informs us about the mechanisms of action of the dopaminergic therapies used to treat it. By doing so, we will highlight some of the paradoxes that exist and how solving them may reveal new insights for improved treatment of this currently incurable condition, including the possibility that such drugs may even have effects on disease progression and pathogenesis.

[1]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Fuxe,et al.  The dopamine stabilizers ACR16 and (−)-OSU6162 display nanomolar affinities at the σ-1 receptor , 2013, Molecular Psychiatry.

[3]  Nir Giladi,et al.  Olanzapine in Huntington's disease , 2002, Acta neurologica Scandinavica.

[4]  N. Volkow,et al.  Measuring dopamine release in the human brain with PET , 1995 .

[5]  Diego Mantovani,et al.  Mutant huntingtin is present in neuronal grafts in huntington disease patients , 2014, Annals of neurology.

[6]  P. Greengard,et al.  The neurobiology of dopamine signaling , 2002, European Psychiatry.

[7]  Carlos Cepeda,et al.  Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice , 2008, The Journal of Neuroscience.

[8]  A. Parent,et al.  Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. , 2011, Parkinsonism & related disorders.

[9]  P. Calabresi,et al.  A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine–acetylcholine synaptic balance , 2006, The Lancet Neurology.

[10]  W. Mcbride,et al.  Neurochemical changes following the administration of depleters of biogenic monoamines. , 1976, Life sciences.

[11]  P. Soares-da-Silva,et al.  Increased Cerebrospinal Fluid Dopamine and 3,4‐Dihydroxyphenylacetic Acid Levels in Huntington's Disease: Evidence for an Overactive Dopaminergic Brain Transmission , 1992, Journal of neurochemistry.

[12]  C. Pagès,et al.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Nicola Pavese,et al.  Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. , 2003, Brain : a journal of neurology.

[14]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[15]  D. Brooks,et al.  Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.

[16]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[17]  D. Brooks,et al.  Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome , 2000, Journal of neurology, neurosurgery, and psychiatry.

[18]  Joseph Jankovic,et al.  Tetrabenazine Treatment for Huntington's Disease-Associated Chorea , 2002, Clinical neuropharmacology.

[19]  H. Leijnse-Ybema,et al.  HUNTINGTON'S CHOREA AND LEVODOPA , 1974 .

[20]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[21]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[22]  M. Trabucchi,et al.  Acute treatment of Huntington's chorea with lisuride , 1983, Journal of the Neurological Sciences.

[23]  P. Spano,et al.  Effects of bromocriptine on central dopaminergic receptors. , 1976, Life sciences.

[24]  A. Sidhu,et al.  Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation , 2004, Molecular and Cellular Neuroscience.

[25]  F. Pettersson,et al.  Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). , 2010, Journal of medicinal chemistry.

[26]  R. Barker,et al.  Emerging drug therapies in Huntington's disease , 2009, Expert opinion on emerging drugs.

[27]  F. Pettersson,et al.  In vivo pharmacology of the dopaminergic stabilizer pridopidine. , 2010, European Journal of Pharmacology.

[28]  B. D. de Jong,et al.  Changes in striatal dopamine D2 receptor binding in pre‐clinical Huntington’s disease , 2008, European journal of neurology.

[29]  B. Dubois,et al.  Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. , 2006, Cerebral cortex.

[30]  Y. Bordelon.  Clinical neurogenetics: huntington disease. , 2013, Neurologic clinics.

[31]  J. Jankovic,et al.  A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease , 2008, Clinical neuropharmacology.

[32]  B. Tan,et al.  Levodopa in Huntington's chorea. , 1972, Lancet.

[33]  K. Biglan,et al.  Therapeutics in Huntington’s Disease , 2012, Current Treatment Options in Neurology.

[34]  E. Parati,et al.  Effects of DA agonist in Huntington disease hyperkinesia , 1979, The Italian Journal of Neurological Sciences.

[35]  S. Kapur,et al.  The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[36]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[37]  O. Hansson,et al.  Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Barker,et al.  Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers , 2010, Neurobiology of Disease.

[39]  S. W. Davies,et al.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[41]  Chris Frost,et al.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data , 2012, The Lancet Neurology.

[42]  A. Rego,et al.  Mechanisms of neurodegeneration in Huntington’s disease , 2008, European Journal of Neuroscience.

[43]  E T Bullmore,et al.  Substantia nigra/ventral tegmental reward prediction error disruption in psychosis , 2008, Molecular Psychiatry.

[44]  A. Carlsson,et al.  Schizophrenia: from dopamine to glutamate and back. , 2004, Current medicinal chemistry.

[45]  D. Calne,et al.  Bromocriptine in Huntington chorea. , 1976, Archives of neurology.

[46]  B. Leavitt,et al.  A randomized, double‐blind, placebo‐controlled trial of pridopidine in Huntington's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[47]  R N Gunn,et al.  Huntington's disease progression. PET and clinical observations. , 1999, Brain : a journal of neurology.

[48]  E. Abercrombie,et al.  In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease , 2011, Front. Syst. Neurosci..

[49]  A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study , 1996, Journal of psychopharmacology.

[50]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[51]  E T Bullmore,et al.  How dopamine dysregulation leads to psychotic symptoms? Abnormal mesolimbic and mesostriatal prediction error signalling in psychosis , 2008, Molecular Psychiatry.

[52]  A. Jennifer Morton,et al.  Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation , 2008, Brain Research.

[53]  Michael Petrides,et al.  The Neural Circuitry of Executive Functions in Healthy Subjects and Parkinson's Disease , 2010, Neuropsychopharmacology.

[54]  Jeffrey H Kordower,et al.  Animal models of Huntington's disease. , 2007, ILAR journal.

[55]  R. Wightman,et al.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.

[56]  P. Seeman,et al.  Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors , 1998, Molecular Psychiatry.

[57]  L. Smeeth,et al.  Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[58]  M. Hayden,et al.  Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. , 2012, Human molecular genetics.

[59]  A. Bentivoglio,et al.  The Long-term Effect of Tetrabenazine in the Management of Huntington Disease , 2008, Clinical neuropharmacology.

[60]  G. Nagy,et al.  Prolactin: structure, function, and regulation of secretion. , 2000, Physiological reviews.

[61]  E. Spokes,et al.  Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. , 1980, Brain : a journal of neurology.

[62]  Handbook of Chemical Neuroanatomy: Dopamine , 2005 .

[63]  Marios Politis,et al.  Hypothalamic involvement in Huntington's disease: an in vivo PET study. , 2008, Brain : a journal of neurology.

[64]  C. Cepeda,et al.  Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility , 2013, Front. Neurosci..

[65]  Hitoshi Takahashi,et al.  A quantitative investigation of the substantia nigra in Huntington's disease , 1989, Annals of neurology.

[66]  A. Grace.  The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. , 2000, Addiction.

[67]  C. Halldin,et al.  Extrastriatal dopamine D2 receptor binding in Huntington's disease , 2011, Human brain mapping.

[68]  D. Sulzer,et al.  Expanded CAG repeats in exon 1 of the Huntington's disease gene stimulate dopamine-mediated striatal neuron autophagy and degeneration. , 2001, Human molecular genetics.

[69]  W. Ondo,et al.  Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. , 2012, Clinical therapeutics.

[70]  R. Albin,et al.  Decreased striatal monoaminergic terminals in Huntington disease , 2000, Neurology.

[71]  David W. Miller,et al.  Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology. , 2003, Brain research. Molecular brain research.

[72]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[73]  C D Marsden,et al.  A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[74]  N. Narayanan,et al.  Prefrontal dopamine signaling and cognitive symptoms of Parkinson’s disease , 2013, Reviews in the neurosciences.

[75]  E. Borrelli,et al.  Structure and function of dopamine receptors , 2000, Neuroscience & Biobehavioral Reviews.

[76]  R. Barker,et al.  Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial , 2011, The Lancet Neurology.

[77]  J. Jankovic,et al.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias , 1988, Neurology.

[78]  Amber N. Baysinger.  Principles of Cognitive Neuroscience , 2015, The Yale Journal of Biology and Medicine.

[79]  E. Bird,et al.  Chemical pathology of Huntington's disease. , 1980, Annual review of pharmacology and toxicology.

[80]  T. Robbins.  Chemistry of the mind: Neurochemical modulation of prefrontal cortical function , 2005, The Journal of comparative neurology.

[81]  Toshiyuki Sato,et al.  Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal. , 2010, European journal of pharmacology.

[82]  G. Tribl,et al.  High-dose olanzapine in Huntington's disease. , 2002, International clinical psychopharmacology.

[83]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[84]  G. Reynolds,et al.  The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease , 2002, Journal of neurochemistry.

[85]  I. Bezprozvanny,et al.  Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. , 2010, Future neurology.

[86]  D. Sulzer,et al.  CARGO RECOGNITION FAILURE IS RESPONSIBLE FOR INEFFICIENT AUTOPHAGY IN HUNTINGTON’S DISEASE , 2010, Nature Neuroscience.

[87]  Jane S. Paulsen,et al.  Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. , 2008, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[88]  D. Craufurd,et al.  A Europe‐wide assessment of current medication choices in Huntington's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[89]  J. Jankovic,et al.  Long-term effects of tetrabenazine in hyperkinetic movement disorders , 1997, Neurology.

[90]  S. Frank.  Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators , 2009, BMC neurology.

[91]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[92]  Aman A. Savani,et al.  Practice Advisory: Utility of surgical decompression for treatment of diabetic neuropathy: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2007, Neurology.

[93]  A. Ciarmiello,et al.  Aripiprazole in the treatment of Huntington’s disease: a case series , 2008, Neuropsychiatric disease and treatment.

[94]  J. Whittier,et al.  Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (prolixin) , 2005, Psychiatric Quarterly.

[95]  R. Albin,et al.  Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers , 2001, Synapse.

[96]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[97]  R. Roos,et al.  Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study , 1997, Journal of neurology, neurosurgery, and psychiatry.

[98]  T. Robbins,et al.  Role of Dopamine D2 Receptors in Human Reinforcement Learning , 2014, Neuropsychopharmacology.

[99]  S. Frank.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease , 2010, Neuropsychiatric disease and treatment.

[100]  Xi Chen,et al.  Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.

[101]  E. Dietrichs,et al.  Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease , 2010, Clinical neuropharmacology.

[102]  D. Mateo,et al.  [Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]. , 1989, Neurologia.

[103]  Nicola Biagio Mercuri,et al.  Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine , 2009, Movement disorders : official journal of the Movement Disorder Society.

[104]  W. Koller,et al.  The gait abnormality of Huntington's disease , 1985, Neurology.

[105]  S. Floresco,et al.  Mesocortical dopamine modulation of executive functions: beyond working memory , 2006, Psychopharmacology.

[106]  E. Parati,et al.  Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[107]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[108]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[109]  C. Pagès,et al.  Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo , 2008, Neurobiology of Disease.

[110]  Jane S. Paulsen,et al.  Detection of Huntington’s disease decades before diagnosis: the Predict-HD study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[111]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[112]  O. Riess,et al.  Motor function and dopamine release measurements in transgenic Huntington's disease model rats , 2012, Brain Research.

[113]  C. Huang,et al.  Tetrabenazine in the treatment of Huntington's chorea. , 1976, The Medical journal of Australia.

[114]  R. Ferrante,et al.  Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum , 1987, Brain Research.

[115]  Michael A. Johnson,et al.  Impaired dopamine release and uptake in R6/1 Huntington's disease model mice , 2011, Neuroscience Letters.

[116]  J. Mink.  THE BASAL GANGLIA: FOCUSED SELECTION AND INHIBITION OF COMPETING MOTOR PROGRAMS , 1996, Progress in Neurobiology.

[117]  M. Hayden,et al.  Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.

[118]  G. Paulson,et al.  Predictive test for Huntington's chorea. , 1970, Lancet.

[119]  D. Surmeier,et al.  D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons , 2007, Trends in Neurosciences.

[120]  S. Krajewski,et al.  Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II , 2008, Human molecular genetics.

[121]  J. Adámek,et al.  Volumes , 2012, Techniques du bâtiment : préparer la construction.

[122]  Jianfang Chen,et al.  Characterization of Striatal Neuronal Loss and Atrophy in the R6/2 Mouse Model of Huntington’s Disease , 2014, PLoS currents.

[123]  P. Brundin,et al.  Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of Transgenic Huntington's Disease Mice , 2002, Neurobiology of Disease.

[124]  David Housman,et al.  Huntington's Disease: Can Mice Lead the Way to Treatment? , 2011, Neuron.

[125]  R. Bonelli,et al.  Olanzapine for Huntington's disease: An open label study , 2002, European Neuropsychopharmacology.

[126]  R. Truhaut,et al.  HUMAN CARCINOGENESIS , 1976, The Lancet.

[127]  F. Jamali,et al.  Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. , 1987, Journal of pharmaceutical sciences.

[128]  G. Reynolds,et al.  Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease , 1988, Neuropharmacology.

[129]  C. Loeb,et al.  Levodopa and Huntington's chorea , 1976, Journal of neurology, neurosurgery, and psychiatry.

[130]  T. Sotnikova,et al.  Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[131]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[132]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[133]  T. Bonner,et al.  Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[134]  A. Porcellini,et al.  Short-term effects of olanzapine in Huntington disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[135]  M. McGlamery,et al.  Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders. , 1978, The Journal of clinical psychiatry.

[136]  J. Jankovic,et al.  Short‐term effects of tetrabenazine on chorea associated with Huntington's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[137]  S. P. Hunt,et al.  Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea , 1988, Neuroscience.

[138]  M. Dragunow,et al.  The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease , 2000, Neuroscience.